Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


State Rx Rebates For Non-Medicaid Populations Backed By Kerry

Executive Summary

The administration of Democratic presidential nominee John Kerry would support using Medicaid prior authorization lists to obtain drug rebates for non-Medicaid populations

You may also be interested in...

Kerry/Edwards Medicare Rx “Overhaul” Plan: Negotiation, Not Dictation

Democratic presidential candidate John Kerry's plans to "overhaul" the Medicare Rx legislation would not involve direct price setting by the federal government, Kerry Campaign Policy Director Sarah Bianchi maintained during the Banc of America Washington Health Care Conference July 7

Supreme Court Allows Maine Rx; PhRMA Says States Will Delay Similar Plans

The Pharmaceutical Research & Manufacturers of America believes that until Maine issues regulations to implement Maine Rx, other states will wait before proceeding with similar programs

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts